Skip to content

Effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in Emerging Adults

Effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in Emerging Adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07798063
Enrollment
50
Registered
2026-09-01
Start date
2026-01-05
Completion date
2026-12-28
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder (GAD)

Brief summary

This study will evaluate whether Solution-Focused Therapy (SFT) helps reduce symptoms of Generalized Anxiety Disorder (GAD) in emerging adults in Pakistan. Participants will first be screened to identify those with mild to moderate levels of GAD. Eligible participants will be randomly assigned to receive either SFT or be placed on a waitlist. The researcher will measure changes in anxiety symptoms before and after the intervention to determine whether SFT is effective for emerging adults with GAD in Pakistan.

Detailed description

Anxiety disorders are common worldwide, and anxiety and stress symptoms are particularly prevalent among university students in Pakistan. Emerging adulthood is a critical developmental period characterized by significant transitions, identity exploration, and heightened stress, during which Generalized Anxiety Disorder (GAD) can emerge. GAD is characterized by excessive and persistent anxiety and worry related to different areas of life, including work, family, health, or finances. Although conventional psychological therapies are available for such mental health problems, they can be time-consuming and costly. Therefore, shorter and effective psychological interventions are needed. Solution-Focused Therapy (SFT) has been supported by research as an approach in which fewer sessions may be sufficient for improving psychological symptoms. However, there is limited literature on the effectiveness of SFT for emerging adults with anxiety disorders in Pakistan, and the intervention has not been culturally validated for Pakistani emerging adults with GAD. This study aims to examine the effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in emerging adults in Pakistan. The study will use a randomized controlled trial design. Emerging adults aged 18-29 years will first be screened using the Generalized Anxiety Disorder 7-item (GAD-7) Scale to identify participants with mild to moderate levels of GAD. Eligible participants will then be randomly assigned to a treatment group receiving SFT or a waitlist control group. The SFT intervention will be applied to participants with GAD to examine its effectiveness in reducing their anxiety symptoms. The study will assess changes in GAD symptoms before and after the intervention to determine the effectiveness of SFT among emerging adults with GAD in Pakistan. It is expected that participants receiving SFT will show a decline in GAD symptoms compared with the waitlist control group. The study will provide evidence regarding the effectiveness of a brief and culturally relevant SFT intervention for emerging adults with GAD in the Pakistani context.

Interventions

BEHAVIORALSolution-Focused Therapy

Participants in intervention group will receive Solution-Focused Therapy. The program includes approximately 6-8 individual sessions (45-60 minutes) covering goal-setting, exception-finding, scaling questions, the miracle question, identification of existing strengths and resources, and construction of solution-focused action steps.

Sponsors

International Islamic University, Islamabad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 29 Years
Healthy volunteers
Yes

Inclusion criteria

Participants with mild to moderate scores of generalized anxiety disorder upon baseline assessment will be included in the study.

Exclusion criteria

Individuals will be excluded if they reported a diagnosis of psychotic disorder, and those receiving psychotherapy or counseling for anxiety.

Design outcomes

Primary

MeasureTime frameDescription
Generalized Anxiety Disorder 7-item (GAD-7)Baseline and Week 8The Generalized Anxiety Disorder 7-item (GAD-7) scale assesses severity of anxiety symptoms. Total scores range from 0 to 21. Higher scores indicate more severe anxiety symptoms.
Depression Anxiety Stress Scales - Short Form (DASS-21)Baseline and Week 8The Depression Anxiety Stress Scales - Short Form (DASS-21) measures emotional distress. The total score ranges from 0 to 63 (combining depression, anxiety, and stress subscales). Higher scores indicate more severe emotional distress.

Secondary

MeasureTime frameDescription
Intolerance of Uncertainty Scale - Short Form (IUS-12)Baseline and Week 8The Intolerance of Uncertainty Scale - Short Form assesses reactions to ambiguous situations. Total scores range from 12 to 60. Higher scores indicate a greater intolerance of uncertainty.
Negative Problem Orientation Questionnaire (NPOQ)Baseline and Week 8The Negative Problem Orientation Questionnaire (NPOQ) evaluates dysfunctional cognitive attitudes toward problem-solving. Total scores range from 12 to 60. Higher scores indicate a more negative problem orientation.
Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)Baseline and Week 8The Difficulties in Emotion Regulation Scale - Short Form (DERS-SF) assesses emotion dysregulation. Total scores range from 18 to 90. Higher scores indicate greater difficulty in regulating emotions.
Brief Resilience ScaleBaseline and Week 8The Brief Resilience Scale (BRS) measures the ability to recover from stress. Total scores range from 6 to 30. Higher scores indicate greater resilience (a better outcome).

Countries

Pakistan

Contacts

CONTACTFariha Hayat, MS
fariha.hayat87@gmail.com+92 3365288229
PRINCIPAL_INVESTIGATORFariha Hayat, MS

International Islamic University, Islamabad

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026